CIK 0001434647 · Non-accelerated filer<br>Smaller reporting company
ZEVRA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ZVRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205894398
- Phone
- (888) 958-1253
- Business address
- 101 FEDERAL STREET, BOSTON, MA, 02110
- Former names
- KEMPHARM, INC, KEMPHARM INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $224,948
- in 1 filing, $225K under 10b5-1 plans
Net −$224,948. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-12 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −20,000 | $11.25 | $225K | 417,225 |
| 2026-08-14 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −42,666 | $11.13 | $475K | 37,569 |
| 2026-08-10 | Watton Corey Michael Director | Sale | −12,300 | $11.25 | $138K | 1,800 |
| 2026-06-22 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −34,557 | $12.68 | $438K | 80,235 |
| 2026-05-11 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −1,794 | $11.30 | $20K | 48,125 |
| 2026-02-09 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −14,625 | $8.56 | $125K | 387,225 |
| 2026-02-03 | Schafer Joshua CCO | Sale 10b5-1 | −10,500 | $9.19 | $97K | 62,278 |
| 2026-02-03 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 | −3,000 | $9.18 | $28K | 29,590 |
| 2026-02-02 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −91,000 | $9.38 | $853K | 364,350 |
| 2026-01-30 | Schafer Joshua CCO | Sale 10b5-1 | −3,375 | $8.83 | $30K | 37,444 |
| 2026-01-30 | Quartel Adrian W Chief Medical Officer | Sale 10b5-1 | −4,533 | $8.83 | $40K | 9,723 |
| 2026-01-30 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −4,080 | $8.83 | $36K | 49,919 |
| 2026-01-30 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 | −1,750 | $8.82 | $15K | 20,924 |
| 2025-10-10 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −19,500 | $10.82 | $211K | 222,016 |
| 2025-06-26 | Thompson Rahsaan Chief Legal & Compliance | Sale 10b5-1 | −24,000 | $9.21 | $221K | 42,666 |
| 2025-02-14 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −30,544 | $8.05 | $246K | 191,516 |
| 2025-02-13 | Sangiovanni Timothy J. SVP, Finance & Corp Controller | Sale 10b5-1 | −3,000 | $7.86 | $24K | 16,341 |
| 2025-02-13 | Schafer Joshua CCO & EVP, Bus. Development | Sale 10b5-1 | −10,500 | $7.86 | $83K | 29,486 |
| 2025-02-13 | Clifton R. LaDuane CFO & Treasurer | Sale 10b5-1 | −11,000 | $7.86 | $86K | 51,361 |
| 2025-02-13 | McFarlane Neil F. President and CEO | Sale 10b5-1 | −61,273 | $7.86 | $481K | 222,060 |
Page 1 of 1 · 20 trades